Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

ational compound.  Afatinib is not approved by the FDA; its safety and efficacy have not been established. 

Afatinib is an investigational oral, once-daily irreversible ErbB Family Blocker that specifically inhibits epidermal growth factor receptor (EGFR or ErbB1), human epidermal receptor 2 (HER2 or ErbB2), ErbB3 and ErbB4.  It is currently in phase III clinical development in NSCLC, head and neck and breast cancer. 

About the Afatinib Clinical Trial Program in Advanced NSCLCThe LUX-Lung studies evaluate the use of afatinib in various settings of advanced NSCLC, including in patients harboring EGFR mutations and those with recurrent disease.  These trials include:

  • LUX-Lung 1, a Phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and the reversible EGFR TKIs erlotinib or gefitinib.
  • LUX-Lung 2, a Phase II trial evaluating afatinib in NSCLC patients with EGFR mutations (EGFR M+), either treatment-naive or after one line of treatment with chemotherapy.
  • LUX-Lung 3, a Phase III trial investigating afatinib as a first-line treatment in patients with advanced NSCLC with EGFR mutations. 
  • LUX-Lung 4, a Phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment. 
  • LUX-Lung 5, a global Phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized Phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.
  • LUX-Lung 6, a Phase III trial investigating the efficacy and safety of afatinib compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations.
  • LUX-Lung 7, a Phase IIb trial e
    '/>"/>

  • SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    4. Boehringer Ingelheim Unveils Diabetes Pipeline
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
    11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... Feb. 27, 2015 An aggressive campaign to ... the rate of infection with a dangerous drug-resistant bacteria ... Clostridium difficile, or C.diff, is a bacterium that ... of the colon. A recent article in the New ... Infection in the United States " ...
    (Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
    (Date:2/27/2015)... 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... financial results for the fourth quarter and full year ... a transformative year for PTC. We are now a ... RNA-targeted therapies in the rare disease space," stated Stuart ... "We are proud to bring the first treatment for ...
    Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
    ... Biotech, Inc. is pleased to,announce that it ... (PCT) patent from Australia, China and India. ... their Method of use for Gut-based,Therapy," protects ... oral,probiotic product formulation (Kibow Biotics(R)) which may ...
    ... Therapies Shows Similar, Sustained Response Rates; Fewer Patients ... ... KENILWORTH, N.J., Jan. 14 Schering-Plough,Corporation (NYSE: SGP ... of the IDEAL study, the first large, randomized, clinical,study comparing ...
    Cached Medicine Technology:Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure 2Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure 3Schering-Plough Reports Top-Line Results of the IDEAL Study 2Schering-Plough Reports Top-Line Results of the IDEAL Study 3Schering-Plough Reports Top-Line Results of the IDEAL Study 4Schering-Plough Reports Top-Line Results of the IDEAL Study 5Schering-Plough Reports Top-Line Results of the IDEAL Study 6Schering-Plough Reports Top-Line Results of the IDEAL Study 7Schering-Plough Reports Top-Line Results of the IDEAL Study 8Schering-Plough Reports Top-Line Results of the IDEAL Study 9
    (Date:2/28/2015)... TN: MedixSafe has retracted a previous announcement from ... named Guardian 2. The correct product name is ... that significantly increases the complexity of security credentials. ... provides fast and easy access for both the ... with Vanguard technology tracks inventory by time, ...
    (Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
    (Date:2/27/2015)... Sacramento, Calif. (PRWEB) February 27, 2015 ... of liver-disease death, between four and 12 years earlier ... study from UC Davis Health System. , While previous ... ALD than other populations, the new study -- published ... -- is believed to be the first to pinpoint ...
    (Date:2/27/2015)... Clara, CA (PRWEB) February 27, 2015 ... Passive Devices (IPD), has introduced miniature, wire bondable, silicon ... and Power LED markets. The ESD88NP ... transient currents away from sensitive LED and IC products. ... to Multilayer Varistors (MLV). All devices meet the ...
    (Date:2/27/2015)... 2015 Just a little over two ... suffering from Sjögren’s Syndrome after a new autoantibody associated ... the University of Buffalo and Immco Diagnostics, Inc. After ... to develop a new diagnostic test that ... new autoantibodies. Researchers aimed to develop a test that ...
    Breaking Medicine News(10 mins):Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2
    ... , , Recognize Excellence in Reporting, Portrayals ... 31 , ALEXANDRIA, Va. , Feb. ... professionals to submit national, state, local and student news and ... the 2010 Media Awards. , Details, including categories and a ...
    ... , , TUCSON, Ariz. , Feb. 9 ... largest companies with over 11,000 employees nationwide, today announced that it ... , Providence , working with Peach Properties, will take over ... to the new site of Tucson Electric Power,s new headquarters. , ...
    ... ... extensive smile gallery and other resources and tools for patients , ... New York, NY (PRWEB) February 9, 2010 -- Leading ... the launch of its new Web site, www.SmileInTheCity.com . The site boasts simple navigation, ...
    ... biopsies done in doctor,s office boosted overall spending, study ... Medicare sweetened payments for simple office-based endoscopic procedures, doctors ... in-office bladder biopsies, but the volume of hospital procedures ... So, instead of saving money, Medicare expenditures rose 50 ...
    ... Feb. 9 Quantum Health, the Columbus, ... appointed Jim Stark to be Executive Vice President ... Director for Aon Consulting, will oversee Quantum Health,s national sales ... various Blue Cross/Blue Shield plans, national insurance carriers and third ...
    ... ... their teens a gift of knowledge and empowerment, because when romance heats up, teens often ... ... having ,The Talk, is probably one of the most difficult and challenging moments of parenthood. ...
    Cached Medicine News:Health News:Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards 2Health News:Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards 3Health News:Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson 2Health News:Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson 3Health News:Top New York Dentists at Smile in the City Launch New Web Site 2Health News:Medicare Cost-Saving Moves Can Backfire 2Health News:Medicare Cost-Saving Moves Can Backfire 3Health News:Quantum Health Appoints Stark as Executive Vice President of Sales 2Health News:Don't Be a Sex Ed Horror Story — Keep the VD Out of Valentine's Day 2Health News:Don't Be a Sex Ed Horror Story — Keep the VD Out of Valentine's Day 3
    Thermal Seal, Clear, Bulk...
    Mylar Plate Sealers 100/Box...
    OptiTape - Optically Clear sealing tape for OmniUltra PCR plates plus universal dispenser. 250 sheets....
    The Heat Sealing Foil and Heat...
    Medicine Products: